288383-20-0 Cediranib AKSci X2636
 
 
Loading Please Wait...
  X2636    AKSci Reference Standard
Cediranib, 98% (HPLC)
 
AZD2171
IDENTITY
CAS Number:288383-20-0
MDL Number:MFCD09954115
MF:C25H27FN4O3
MW:450.51
SPECIFICATIONS & PROPERTIES
Min. Purity Spec:98% (HPLC)
Physical Form (at 20°C):Solid
Melting Point:146-156°C
Long-Term Storage:Store long-term at -20°C
DOT/IATA TRANSPORT INFORMATION
Not hazardous material

BIOLOGICAL INFO
Solubility:DMSO
Application(s):Vascular endothelial growth factor (VEGF) receptor tyrosine kinases inhibitor
Form:Free Base
Research Area:solid tumours, chronic myeloid leukaemia

REVIEW
 Cediranib (Recentin and AZD2171), is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases, developed by AstraZeneca as a possible anti-cancer chemotherapeutic agent against a variety of solid malignancies for oral administration. The drug has shown promising, in preclinical models and in clinical trials. Its pharmacokinetics allow for a convenient once-daily administration. Clinical trials are still evaluating the role of cediranib in combination chemotherapy with cytotoxic agents.

REFERENCES
[1]Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR, Smith NR, James NH, Dukes M, Curwen JO, Chester R, Jackson JA, Boffey SJ, Kilburn LL, Barnett S, Richmond GH, Wadsworth PF, Walker M, Bigley AL, Taylor ST, Cooper L, Beck S, Jürgensmeier JM, Ogilvie DJ, AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 2005 May 15;65(10):4389-400.
[2] Hanrahan EO, Heymach JV. Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer. Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4617-22.
[3] Nikolinakos P, Heymach JV. The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies. J Thorac Oncol. 2008 Jun;3(6 Suppl 2):S131-4.
[4] Goss G, Shepherd FA, Laurie S, Gauthier I, Leighl N, Chen E, Feld R, Powers J, Seymour L, A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer. 2009 Mar;45(5):782-8.

GLOBALLY HARMONIZED SYSTEM (GHS)

Pictograms

Signal Word
Warning

Hazard Statements
H315; H319; H335

Precautionary Statements
P261; P264; P271; P280; P302+P352; P304+P340; P305+P351+P338; P312; P321; P332+P313; P337+P313; P362; P403+P233; P405; P501

Current as of April 21, 2026

AKSci Reference Standards are high-purity, low-impurity compounds suitable for use as standards.


Download SDS Request COA

All products are stocked and shipped from the SF Bay, California, USA via FedEx, UPS or DHL.
All batches backed with full quality assurance.
⚠️
All products are for research and development use only, not for any other uses, and must be handled by technically-qualified persons.

These products are explicitly not intended to be used in foods and/or cosmetics and/or drugs (human and veterinary) and/or consumer products and/or biocides and/or pesticides of any kind unless explicitly stated otherwise.

Products are not sold to individuals. We do not ship to residential addresses. Consumer orders will be cancelled without notice.

New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. Additional restrictions may apply.


CATEGORIES
 APIs and Bioactives >


PubChem
  @PubMed